Zydus receives USFDA approval for Niacin Extended-Release Tablets
Zydus Lifesciences has received final approval from the United States Food and Drug Administration (USFDA) to manufacture Niacin Extended-Release Tablets USP, 500 mg, 750 mg, and 1,000 mg (Niaspan Extended-Release Tablets, 500 mg, 750 mg, and 1,000 mg).
Niacin is indicated to reduce elevated total cholesterol (TC), LDL cholesterol (LDL-C), apolipoprotein B (Apo B), and triglycerides (TG), and to increase HDL cholesterol (HDL-C) in patients with primary hyperlipidaemia and mixed dyslipidaemia. It is also indicated to reduce the risk of recurrent myocardial infarction in patients with a history of myocardial infarction and hyperlipidaemia and to reduce TG in adult patients with severe hypertriglyceridemia. Niacin-Extended-Release tablets will be produced at the Group's manufacturing site at Moraiya, Ahmedabad.
Niacin-Extended-Release tablets had annual sales of USD 5.5 mn in the United States (IQVIA MAT February 2025).
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Fashion Value Chain
a day ago
- Fashion Value Chain
Emcutix Unveils Flawlizo Range for Rapid Acne Relief
Emcutix Biopharmaceuticals Ltd., a subsidiary of Emcure Pharmaceuticals, has entered the anti-acne skincare market with the launch of its Flawlizo Xpert Acne Care range—offering targeted, science-led solutions for fast and effective acne management. The highlight of the consumer range includes: Flawlizo Acne Spot Corrector – a biphasic formulation clinically proven to reduce early breakouts within 3–5 days Flawlizo Acne Care Moisturizing Gel – a non-comedogenic, hydrating solution enriched with natural extracts, designed to nourish acne-prone skin without clogging pores The products are developed to deliver visible results, while maintaining skin barrier integrity and hydration—offering a complete acne care routine that addresses breakout treatment and long-term skin health. In addition to the consumer offerings, the Flawlizo portfolio also includes five prescription-only products featuring Tretinoin, a globally recognized gold-standard acne treatment. These are manufactured at Encube Ethicals, a USFDA-certified facility with one of the largest global capabilities in topical dermatological formulations. Sathya Narayanan, CEO, Emcutix Biopharmaceuticals Ltd., stated: 'Flawlizo reflects our commitment to uniting clinical science with real-world skincare needs. It empowers individuals to manage acne with confidence and care, using safe, effective, and accessible solutions.' This launch reinforces Emcutix's growing footprint in dermatology, spanning prescription, aesthetic, and over-the-counter skincare solutions. The move follows the company's exclusive licensing partnership with WiQo, introducing PRX-PLUS, a non-invasive skin treatment, to the Indian market for the first time.
Time of India
2 days ago
- Time of India
HealthKois launched to support healthcare enterprises
National: Healthcare transformation fund HealthKois has been launched with a target corpus of USD 300 million and an additional green shoe option of USD 100 million. The fund has been established by the leadership team behind HealthQuad —Charles Janssen (Managing Partner), Ajay Mahipal (Partner), and Dr. Pinak Shrikhande (Partner). Positioned as the successor to HealthQuad, HealthKois will invest in technology-enabled, scalable healthcare enterprises. According to the company, the fund aims to deliver risk-adjusted financial returns along with measurable social impact. It is indicated that over the next four years, HealthKois plans to invest between USD 7 million and USD 25 million per company, targeting early growth-stage businesses in HealthTech , Life Sciences , MedTech , Healthcare Delivery, and Climate Health. The fund is intended to focus on companies which have scalable operations, demonstrate clinical outcomes, and have sustainable infrastructure models.
&w=3840&q=100)
Business Standard
3 days ago
- Business Standard
Wockhardt eyes $9 bn market opportunity for novel antibiotic Zaynich
Mumbai-based pharmaceutical major Wockhardt, which is set to launch a new class of antibiotic, Zaynich, in India this year, estimates a total addressable market opportunity of $9 billion. This includes a $7-billion market in the US and Europe, and a ₹17,000-crore opportunity in India. The company's stock rose 2.4 per cent on the BSE on Thursday following an investor presentation outlining its growth plans for the next three to five years. Zaynich (or WCK 5222) is a key research candidate in Wockhardt's pipeline. It has completed global Phase 3 clinical trials, demonstrating a 20 per cent higher (statistically superior) composite cure rate compared to Meropenem, the current gold standard in antibiotics. Wockhardt claims Zaynich is the first new class of antibiotic in over 30 years to treat gram-negative infections. The drug has already saved 51 lives under compassionate use, including three in the US, where patients had failed all existing therapies. Zaynich is indicated for complicated urinary tract infections (UTIs), hospital-acquired and ventilator-associated bacterial pneumonia, bloodstream infections, and complicated intra-abdominal infections. The company expects approval from the Drugs Controller General of India (DCGI) shortly and plans to launch the drug in the second half of this financial year. Wockhardt has completed a pre-NDA (New Drug Application) meeting with the US Food and Drug Administration (USFDA) in May and plans to file in Q2FY26, targeting a potential launch in FY27. Regulatory filings in the EU and emerging markets are scheduled for the second half of FY26. Wockhardt estimates that around 1.1 million patients in India may benefit from Zaynich, while 371,000 carbapenem-resistant cases in the US and Europe are potential candidates. Overall, there are 4.3 million hospitalised cases involving key gram-negative pathogens in the US and EU. The firm sees a combined addressable patient pool of 2 million across India, the US, Europe, and China. Apart from Zaynich, Wockhardt is also betting on other antibiotics in its portfolio, such as Miqnaf (Nafithromycin), and its biotechnology portfolio, including insulin products. Miqnaf, already launched in India, treats community-acquired bacterial pneumonia (CABP) and upper respiratory tract infections. It has received Qualified Infectious Disease Product (QIDP) status from the USFDA, signifying unmet medical need, and Breakthrough Medicinal Product (BMP) designation in Saudi Arabia. Miqnaf targets a ₹10,800-crore market in India, with over 96 million potential prescriptions. In the biosimilars segment, Wockhardt is focusing on diabetes care and sees significant opportunity arising as Danish major Novo Nordisk phases out human insulin cartridges. This creates a ₹450-crore opportunity in India and a $157-million market across emerging economies. With only three major players in India, including itself, Wockhardt expects to benefit substantially. The company is doubling its diabetes biosimilars capacity over the next three years to meet growing demand, targeting business growth of 20–25 per cent.
